Intercept Pharmaceuticals (United States)

Institution (Company)

Homepage Wikipedia ROR

Also Known As

Intercept Pharmaceuticals (United States)

290

Publications

62.5K

Citations

Authors

132

Concepts

About

Intercept Pharmaceuticals (United States) is a company institution in New York, United States known for medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	87	27.4K
2	Health Sciences	14	30	9.6K
3	Biochemistry	11	18	6.1K
4	Natural Sciences	7	13	2.1K
5	Social Sciences	2	3	175

Intercept Pharmaceuticals (United States)

290

Publications

62.5K

Citations

Page 1

	Year	Citations
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis Charles Thomas, Antimo Gioiello, Lilia G. Noriega, Cell Metabolism BiochemistryBiliary TractLiver PhysiologyPhysiologyDiabetes	2009	1.7K
Recognition of Unique Carboxyl-Terminal Motifs by Distinct PDZ Domains Zhou Songyang, A. S. Fanning, Chenglai Fu, Science Chemical BiologySequence MotifBiochemistryStructural BioinformaticsProtein Folding	1997	1.4K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis Frederik Nevens, Pietro Andreoné, G. Mazzella, New England Journal of Medicine	2016	1.1K
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal, Gastroenterology Metabolic SyndromeHepatologyNonalcoholic Fatty Liver DiseaseLiver PhysiologyDiabetes	2013	906
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development Juliette Mouriès, Paola Brescia, Alessandra Silvestri, Journal of Hepatology	2019	618
TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading Thijs W.H. Pols, Mitsunori Nomura, Taoufiq Harach, Cell Metabolism InflammationVascular DiseaseImmunologyEndothelial DysfunctionChronic Inflammation	2011	558
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid Gideon M. Hirschfield, Andrew L. Mason, Velimir A. Luketic, Gastroenterology	2014	551
Services for Adolescents With Psychiatric Disorders: 12-Month Data From the National Comorbidity Survey–Adolescent E. Jane Costello, Jianping He, Nancy A. Sampson, Psychiatric Services	2013	438
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice Eleni Beli, Yuanqing Yan, Leni Moldovan, Diabetes	2018	371

Page 1